PHARMA IN FLUX, in one report a giant revenue gap, in another a surge in sales, but the huge patent cliff is now fading, while 50% of new approvals will be biologicals. Chaos equals opportunity for those who are observant and decisive.
http://www.pharmatimes.com/mobile/13-07-02/pharma_set_for_growth_surge_to_2018_study_forecasts.aspx?r=1
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022